Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
Immuneering Corporation announced that it will present new analyses at the AACR Conference demonstrating that their drug candidate, atebimetinib, exhibits a dual mechanism by both reducing tumor volume and preserving body mass in pancreatic cancer patients, potentially extending overall survival. The findings build on previous data showing 84% of t…